Tamarix Pharma

Tamarix Pharma was founded in 2021 based on technology licensed from the National Institute for Biotechnology in the Negev (Israel) and is focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.

The company’s lead assets, VBIT-4 and VBIT-12, are small molecules designed to target a key mitochondrial process known as VDAC1 oligomerization. VDAC1 oligomerization is a key process involved in apoptotic cell death that has been validated by multiple independent research groups as an anti-apoptotic target.

According to the company its unique mechanism of action represents a highly-differentiated approach to potentially treating a variety of acute and chronic conditions resulting from apoptotic cell death. Early exploration of indications for VBIT-4 and VBIT-12 will include: dry age-related macular degeneration (dry AMD) / geographic atrophy (GA); low-tension glaucoma – intraocular pressure (IOP) independent therapy; and central vein occlusion.

Tamarix plans to be Phase I ready by the end of 2023 and is says it is currently expanding its investor base to support development of VBIT-4 (primary focus) and VBIT-12.

Subscribe for alerts on new companies featured on Startups.Bio

Archon Biosciences
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Cytospire Therapeutics
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
This Week in Biotech Venture Capital
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …

View all recently featured startups

Tags: